Cartilage Regenerating therapy, Invossa, pulled from market despite lack of evidence of harm

The health authorities canceled the license for Kolon Life Sciences' osteoarthritis gene therapy drug Invossa, Tuesday, over the mislabeling of a key ingredient. In addition, they have decided to pursue criminal charges against the pharmaceutical firm.Invossa was the first regenerative gene therapy drug for patients with the degenerative joint disease. The Ministry of Food and Drug Safety approved it use in Korea...

Researchers discover placental stem cells that can regenerate heart after heart attack

Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that stem cells derived from the placenta known as Cdx2 cells can regenerate healthy heart cells after heart attacks in animal models. The findings, published in the May 20 issue of Proceedings of the National Academy of Sciences (PNAS), may represent a novel treatment for regenerating the heart and other organs.

Inhibiting Macrophage Death May Offer New Therapy for Rheumatoid Arthritis

A collaborative study by research groups from the University of Cologne, VIB, Ghent University, the Βiomedical Sciences Research Center ‘Alexander Fleming’ in Athens and the University of Tokyo identified a new molecular mechanism causing rheumatoid arthritis. The researchers found that death of macrophages, an immune cell type, can trigger the disease. Moreover, they discovered how the protein A20...

Brain Cancer Halted in Mice Using Antihistamine Drug

Glioblastoma is the most prevalent and also the most lethal type of brain tumour in adults, with no curative treatment currently available. Glioblastomas cannot be surgically completely excised, as the tumour cells are adept at invading tissues and spreading around the brain. In addition, glioblastoma cells are extremely resistant to existing drug therapies. For a long time, researchers have been...

Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-HBVS for the Treatment of Chronic Hepatitis B Virus

Dicerna Pharmaceuticals announced the dosing of the first patient in its Phase 1 clinical trial of DCR-HBVS, the Company’s investigational GalXCTM-based therapy for the treatment of chronic hepatitis B virus (HBV) infection in adults. The Company anticipates human proof-of-concept data from the Phase 1 trial, which is known as DCR-HBVS-101, in the fourth quarter of 2019. In January...

Gene repair improves memory and seizures in adult autism model

A new study challenges the presumption that people born with developmental brain disorders such as severe autism will benefit from medical interventions only if treated during a narrow window in infancy or early childhood. Writing in the journal eLife, an open-access scientific journal, the Rumbaugh lab at Scripps Research in Florida reports improvement in measures of seizure and memory in...

Semma Therapeutics Announces Publication Demonstrating Advancements in Regenerative Cell Therapy for Type 1 Diabetes

Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced the journal Nature published data demonstrating improvements in the production of beta cells (cells that produce insulin) from stem cells. Led by Harvard University researchers in collaboration with scientists from Semma, the study characterized the types of cells produced by the applicable cell differentiation methods,...

Nabriva Therapeutics Submits Marketing Authorization App for Lefamulin to Treat Community-Acquired Pneumonia

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced that the Company’s  marketing authorization application (MAA) for both the intravenous (IV) and oral formulations of lefamulin, a potentially first-in-class, semi-synthetic pleuromutilin antibiotic, for the treatment of community-acquired pneumonia (CAP) in adults 18 years of age and older, has been submitted to...